Whitehawk Therapeutics Inc
NASDAQ:WHWKBiotechnology
+$0.06 today
- Market cap
- $184.70M
- Beta
- 0.77
- P/E (TTM)
- -2.6
- EPS (TTM)
- -$1.67
Volume 0.28M
Average 0.31M
WHWK Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Whitehawk Therapeutics IncNASDAQ: WHWK
Capital Expenditures · Q4 FY2025 · quarter ended Dec 2025
Capital expenditures turns positive
Q4 FY2025 capital expenditures was $0, compared with -$186K a year earlier. Trailing-twelve-month capital expenditures was -$552K. Over 3 fiscal years it compounded at +7.5% a year.
Context
- Capital expenditures amounted to 7.7% of revenue in FY2025, up 1.4 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$138K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (552K) USD
- Year-over-year change
- +66.6%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (552K) | +66.6% |
| FY2024 | 2024-12-31 | (1.65M) | +58.4% |
| FY2023 | 2023-12-31 | (3.97M) | -794.6% |
| FY2022 | 2022-12-31 | (444K) | -865.2% |
| FY2021 | 2021-12-31 | (46K) | — |
Capital Expenditures vs competitors
How WHWK compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -66.6% is the 6th highest of 9, against a peer median of -31.9%.
- Capital expenditures amounts to 7.7% of revenue for WHWK, versus a peer median of 1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.73M USD | -37.7% | -19.2% | 1.1% | |
| LTM Mar 2026 | $697.7K USD | -26.1% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $552K USD | -66.6% | +7.5% | 7.7% |
| LTM Mar 2026 | $112K USD | -95.7% | -40.3% | — | |
| LTM Mar 2026 | $39K USD | +874.9% | -80.4% | 29.1% | |
| LTM Mar 2026 | $37.26K USD | -9.7% | -60.2% | — | |
| LTM Mar 2026 | $34K USD | -81.2% | — | — | |
| LTM Mar 2026 | CA$15.65K CAD | -91.9% | -46.9% | — | |
| LTM Mar 2026 | $0 USD | +100.0% | — | 0.0% | |
| Peer median (excluding WHWK) | — | -31.9% | -46.9% | 1.1% | |
Competitors are the stored peer set for WHWK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (110.09M) | (60.51M) | (65.77M) | (63.69M) | (20.6M) |
| Depreciation & Amortization | 105K | 159K | 169K | 193K | 79K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.11M | 9.64M | 11.95M | 10.84M | 9.87M |
| Change in Working Capital | 3.96M | (5.04M) | (3.27M) | 3.72M | 1.93M |
| Accounts Receivables | 14.15M | (1.86M) | (3.63M) | (415K) | (1M) |
| Inventory | 0 | (1.86M) | (3.27M) | 1.12M | 170K |
| Accounts Payables | 0 | 0 | 0 | 0 | 3.92M |
| Other Working Capital | (10.19M) | (1.32M) | 3.62M | 3.02M | (1.16M) |
| Other Non-Cash Items | 81.5M | 6.11M | (2.75M) | (10.61M) | (78.77M) |
| Operating Cash Flow | (22.42M) | (49.64M) | (59.66M) | (59.55M) | (97.43M) |
| Capital Expenditures | (46K) | (444K) | (3.97M) | (1.65M) | (552K) |
| Acquisitions (Net) | 25.2M | 0 | 0 | 0 | 101.29M |
| Purchases of Investments | 0 | (145.19M) | (64.44M) | (36.48M) | (148.69M) |
| Sales of Investments | 0 | 12.75M | 151.62M | 63.34M | 59.85M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 25.15M | (132.89M) | 83.21M | 25.2M | 11.89M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 155M | 72.5M | 0 | 130K | 100M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (4.41M) | 0 | 0 | 0 | 0 |
| Other Financing Activities | (8.78M) | 120K | 326K | (16K) | (5.63M) |
| Financing Cash Flow | 141.8M | 72.62M | 326K | 130K | 94.38M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 64K |
| Net Change in Cash | 144.53M | (109.91M) | 23.87M | (34.22M) | 8.9M |
| Free Cash Flow | (22.47M) | (50.08M) | (63.64M) | (61.2M) | (97.99M) |
Whitehawk Therapeutics Inc
NASDAQ:WHWK
Intrinsic Alpha fair value
Locked
Current Price
$3.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.